Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

Global Ankylosing Spondylitis Treatment Market Outlook

The ankylosing spondylitis treatment market size is being driven by the increasing prevalence of the condition and the growing investment in research and development activities. The market was estimated to be worth USD 4.64 billion in 2022. The market is anticipated to grow at a CAGR of 8.1% during the forecast period of 2023-2031 to reach USD 9.37 billion by 2031.

Ankylosing Spondylitis Treatment Market: Introduction

Ankylosing spondylitis is a type of arthritis that affects the joints of the spine. The disease causes inflammation in the joints and can lead to chronic pain, stiffness, and the eventual fusion of the spine. There is currently no cure for ankylosing spondylitis but there are various treatment options available in the market that aim to manage the symptoms of the disease. The report covers the market for ankylosing spondylitis treatment, including drugs and therapies, and provides a detailed analysis of the market size, growth, and trends.

Ankylosing Spondylitis Epidemiology

Ankylosing spondylitis is a chronic autoimmune disease that affects approximately 0.1% to 1% of the global population. The disease is more common in men than in women, with a male-to-female ratio of approximately 2:1. The disease typically begins in young adulthood and can progress over time, leading to chronic pain, stiffness, and the eventual fusion of the spine.

Ankylosing spondylitis is a chronic inflammatory disorder that affects the spine and sacroiliac joints. The exact cause of the disease is unknown but it is believed to be a combination of genetic and environmental factors. The disease is more common in men than women, and typically affects individuals in their late teens to early 30s.

The treatment options for ankylosing spondylitis are focused on reducing inflammation, managing pain and stiffness, and improving mobility. Nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic agents are commonly used to manage the symptoms of the disease. Physical therapy, exercise, and other forms of rehabilitation are also important components of treatment.

Ankylosing Spondylitis Treatment Market Segmentations

The market can be categorised into drug type, indication type, treatment method, treatment channel, and major regions.

Market Breakup by Drug Type

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Tumour Necrosis Factor (TNF) Inhibitors
  • Interleukin (IL) Inhibitors
  • Others
Market Breakup by Indication Type
  • Medication
  • Reactive Arthritis
  • Psoriatic Arthritis
  • IBD Associated Arthritis
  • Juvenile Spondyloarthropathy
  • Undifferentiated Spondyloarthropathy
  • Others
Market Breakup by Treatment Method
  • Physiotherapy and Exercise
  • Painkillers
  • Biological Treatments
  • Corticosteroids
  • Disease Modifying Anti Rheumatic Drugs (DMARDs)
  • Surgery
  • Others
Market Breakup by Treatment Channel
  • Medication
  • Public
  • Private
Ankylosing Spondylitis Treatment Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Ankylosing Spondylitis Treatment Market Scenario

The global ankylosing spondylitis treatment market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of the disease, growing awareness, and advancements in medical technology are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.

North America dominates the ankylosing spondylitis treatment market, followed by Europe and Asia Pacific. The high prevalence of ankylosing spondylitis in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for ankylosing spondylitis treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

Key Players in the Global Ankylosing Spondylitis Treatment Market

The report gives an in-depth analysis of the key players involved in the ankylosing spondylitis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • AbbVie Inc.
  • Amgen Inc.
  • Gilead Sciences
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Ankylosing Spondylitis (AS) Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.2.2 Cost of Treatment
6.2.3 Regulatory Framework
6.2.3.1 Regulatory Overview
6.2.3.1.1 US FDA
6.2.3.1.2 EU EMA
6.2.3.1.3 INDIA CDSCO
6.2.3.1.4 JAPAN PMDA
6.2.3.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Ankylosing Spondylitis Treatment Market
8.1 Global Ankylosing Spondylitis Treatment Market Overview
8.2 Global Ankylosing Spondylitis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Ankylosing Spondylitis Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Ankylosing Spondylitis Treatment Market Forecast Value (2023-2031)
8.3 Global Ankylosing Spondylitis Treatment Market by Drug Type
8.3.1 Market Overview
8.3.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
8.3.1.2 TNF Inhibitors
8.3.1.3 Others
8.4 Global Ankylosing Spondylitis Treatment Market by Indication Type
8.4.1 Market Overview
8.4.1.1 Reactive Arthritis
8.4.1.2 Psoriatic Arthritis
8.4.1.3 IBD Associated Arthritis
8.4.1.4 Juvenile Spondyloarthropathy
8.4.1.5 Undifferentiated Spondyloarthropathy
8.4.1.6 Others
8.5 Global Ankylosing Spondylitis Treatment Market by Treatment Method
8.5.1 Market Overview
8.5.1.1 Physiotherapy and Exercise
8.5.1.2 Painkillers
8.5.1.3 Biological Treatments
8.5.1.4 Corticosteroids
8.5.1.5 Disease Modifying Anti Rheumatic Drugs (DMARDs)
8.5.1.6 Surgery
8.5.1.7 Others
8.6 Global Ankylosing Spondylitis Treatment Market by Treatment Channel
8.6.1 Market Overview
8.6.1.1 Public
8.6.1.2 Private
8.7 Global Ankylosing Spondylitis Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Ankylosing Spondylitis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Ankylosing Spondylitis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Ankylosing Spondylitis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Ankylosing Spondylitis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Ankylosing Spondylitis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Ankylosing Spondylitis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Abvie, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Amgen Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Eli Lilly & Company
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Gilead Sciences
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Johnson & Johnson (Janssen)
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Pfizer Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Novartis AG
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
16 Global Ankylosing Spondylitis Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings